MedTrace Logo

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication

NCT00869908 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66726

Last updated 2017-01-19

No results posted yet for this study

Summary

This study is conducted in Africa, Asia, South America and Europe. The aim of this observational study is to document the experience with the study insulins when used in routine clinical practice. After the physician's decision to start insulin treatment using NovoMix® 30, Levemir® or NovoRapid® (alone or combined), type 2 diabetics will be eligible to be included in this study at the physician's discretion

Conditions

Interventions

DRUG

insulin aspart

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

DRUG

insulin detemir

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

DRUG

biphasic insulin aspart

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Algeria
  • Argentina
  • Bangladesh
  • China
  • Egypt
  • India
  • Indonesia
  • Iran
  • Jordan
  • Libya
  • Malaysia
  • Mexico
  • Morocco
  • Pakistan
  • Philippines
  • Russia
  • Saudi Arabia
  • Singapore
  • South Korea
  • Taiwan
  • Tunisia
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00869908 on ClinicalTrials.gov